Logo Medical XPRT
Companies
Products
Services
Software
Training
Applications
Sign in
List your business

Advertising options
  1. Home
  2. News
  3. radiation oncology
Show results for
Products
Services
Software
Applications

Companies

News
Articles
Books
Downloads
Videos

Refine by
Date

  • Older

Radiation Oncology Articles & Analysis

45 news found

Neutron Therapeutics and University Hospital of Brussels Announce Their Collaboration to Offer Cancer Patients a Revolutionary New Treatment Method at Institut Jules Bordet

Neutron Therapeutics and University Hospital of Brussels Announce Their Collaboration to Offer Cancer Patients a Revolutionary New Treatment Method at Institut Jules Bordet

It has the potential to revolutionize radiation oncology, having demonstrated compelling success in some of the most difficult-to-treat cancers and in treating patients for whom all other treatment options have been exhausted. ...

ByNeutron Therapeutics, Inc.


Neutron Therapeutics and University Hospital of Brussels Announce Their Collaboration to Offer Cancer Patients a Revolutionary New Treatment Method at Institut Jules Bordet

Neutron Therapeutics and University Hospital of Brussels Announce Their Collaboration to Offer Cancer Patients a Revolutionary New Treatment Method at Institut Jules Bordet

It has the potential to revolutionize radiation oncology, having demonstrated compelling success in some of the most difficult-to-treat cancers and in treating patients for whom all other treatment options have been exhausted. ...

ByNeutron Therapeutics, Inc.


Galera Announces Oral Presentation at 2022 American Society of Clinical Oncology (ASCO) Annual Meeting Detailing Results from Phase 3 ROMAN Trial of Avasopasem

Galera Announces Oral Presentation at 2022 American Society of Clinical Oncology (ASCO) Annual Meeting Detailing Results from Phase 3 ROMAN Trial of Avasopasem

“Our research shows that radiation oncologists and patients cite SOM as the most burdensome radiotherapy toxicity in head and neck cancer treatment, and there are currently no FDA-approved drugs to reduce the incidence or duration of SOM in solid tumors. ...

ByGalera Therapeutics, Inc.


Ackerman Cancer Center Celebrates 2,000 Patients Treated with Proton Therapy

Ackerman Cancer Center Celebrates 2,000 Patients Treated with Proton Therapy

” Proton therapy, a highly advanced form of radiation therapy, targets tumors with greater precision than traditional x-ray-based radiotherapy and can reduce the amount of unnecessary radiation exposure to vulnerable healthy tissue and organs. ...

ByMevion Medical Systems


Blue Earth Diagnostics Highlights Presentations on Axumin® (Fluciclovine F 18) and 18F-Fluciclovine at Upcoming ASTRO Annual Meeting

Blue Earth Diagnostics Highlights Presentations on Axumin® (Fluciclovine F 18) and 18F-Fluciclovine at Upcoming ASTRO Annual Meeting

BURLINGTON, Mass. and OXFORD, UK, October 19, 2021 - Blue Earth Diagnostics, a Bracco company and recognized leader in the development and commercialization of innovative PET radiopharmaceuticals, today announced presentations on Axumin® (fluciclovine F 18) and 18F-fluciclovine at the upcoming American Society for Radiation Oncology (ASTRO) 2021 Annual ...

ByBlue Earth Diagnostics


PreludeDx Presents DCIS Patient Data Comparing Clinicopathological Risk Factors to DCISionRT

PreludeDx Presents DCIS Patient Data Comparing Clinicopathological Risk Factors to DCISionRT

For the first time, there is a personalized medicine tool that identifies which patients benefit from RT and discriminates between patients who have a low or elevated risk of recurrence after lumpectomy and RT,” said Rachel Rabinovitch, MD, Professor, Radiation Oncology, University of Colorado. “We are pleased to share our latest data demonstrating ...

ByPreludeDx


Diffusion Pharmaceuticals Expands its Scientific Advisory Board with the Addition of Leading Radiation and Medical Oncology Experts

Diffusion Pharmaceuticals Expands its Scientific Advisory Board with the Addition of Leading Radiation and Medical Oncology Experts

Lustig, M.D., Professor of Clinical Radiation Oncology and Director of Clinical Operations, Radiation Oncology at Penn Medicine; Chad Tang, M.D., Assistant Professor, Department of Radiation Oncology, University of Texas MD Anderson Cancer Center; Cullen M. ...

ByCervoMed


RTsafe’s core role for the development of German guidelines for a standard, safe and efficient implementation of Single-Isocentric Multi-Focal SRS throughout the country

RTsafe’s core role for the development of German guidelines for a standard, safe and efficient implementation of Single-Isocentric Multi-Focal SRS throughout the country

RTsafe is happy to announce that its PRIME and Pseudopatient 3D phantoms, have been selected by a consortium of high-end German Radiotherapy Institutions – led by the Division of Medical Physics of the Department of Radiation Oncology at the Medical Center of University of Freiburg – towards supporting a study whose results will be used for the ...

ByRTsafe


New Data Show Statistically Significant Reduction in Chronic Cancer-Related Lymphedema with Early Detection Using ImpediMed’s L-Dex® Technology and Intervention

New Data Show Statistically Significant Reduction in Chronic Cancer-Related Lymphedema with Early Detection Using ImpediMed’s L-Dex® Technology and Intervention

Chirag Shah, Director of Breast Radiation Oncology and Director of Clinical Research in the Department of Radiation Oncology at Cleveland Clinic and co-investigator of the PREVENT Trial. ...

ByImpediMed Inc.


GammaTile Therapy Delivers Targeted Radiation to Cancer Cells

GammaTile Therapy Delivers Targeted Radiation to Cancer Cells

Drs. Ondrej Choutka, MD, a neurosurgeon, and Lindsay Sales, MD, a radiation oncologist at Saint Alphonsus Regional Medical Center in Boise, have become the first doctors in the Pacific Northwest to utilize a new treatment for brain tumors. They implanted the FDA-cleared GammaTile therapy in a 44-year-old patient with a malignant brain tumor. The current standard of care for patients with ...

ByGT Medical Technologies, Inc.


Galera Announces Primary Endpoint Met Statistical Significance in Corrected Topline Efficacy Data of Phase 3 ROMAN Trial of Avasopasem

Galera Announces Primary Endpoint Met Statistical Significance in Corrected Topline Efficacy Data of Phase 3 ROMAN Trial of Avasopasem

Corrected topline Phase 3 ROMAN data demonstrate primary endpoint achieved statistical significance in reducing the incidence of radiotherapy-induced severe oral mucositis (p=0.045) Topline results from single-arm Phase 2a trial of avasopasem in Europe in line with the ROMAN trial results Company plans to discuss avasopasem data with the FDA in 2022 Company to host conference call and live ...

ByGalera Therapeutics, Inc.


PreludeDx DCISionRT Predicts Radiation Benefit in Landmark Randomized SweDCIS Clinical Trial

PreludeDx DCISionRT Predicts Radiation Benefit in Landmark Randomized SweDCIS Clinical Trial

The randomized study demonstrates that the DCISionRT test predicts radiation benefit for reducing 10-year local invasive breast cancer risk. ...

ByPreludeDx


Stanford University Partners with Kheiron Medical Technologies to Pioneer Use of AI in New Areas of Oncology

Stanford University Partners with Kheiron Medical Technologies to Pioneer Use of AI in New Areas of Oncology

This endeavour will be referred to as ‘The Kaplan Project’ in honor of Stanford’s former radiation oncology leader, Dr. Henry Kaplan, who in the 1960s developed some of the earliest treatments for lymphoma. ...

ByKheiron Medical Technologies Limited


Trailblazing leader named Melburnian of the Year

Trailblazing leader named Melburnian of the Year

Since moving to Melbourne from West Virginia over 30 years ago, O'Neal has forged a successful career as a lawyer, and in 2013 became the first-ever female president of an AFL club. O'Neal is also a board member of Women’s Housing Ltd – helping disadvantaged and vulnerable women gain access to safe housing. Previous Melburnian of the Year winners include leading medical ...

ByCity of Melbourne


Study Demonstrate Superiority of VeraForm® Marker Over Clips

Study Demonstrate Superiority of VeraForm® Marker Over Clips

Conducted by a joint team of breast surgeons and radiation oncologists at Brown University and Tufts Medical Center, the analysis compared the repeatable delineation of the tumor bed after lumpectomy for radiation therapy planning and treatment as well as safety and effectiveness. ...

ByVidera Surgical Inc.


Melbourne Awards celebrate city’s best and brightest

Melbourne Awards celebrate city’s best and brightest

Lord Mayor Sally Capp said 2021’s finalists have gone above and beyond to make our city better. “We’re thrilled to recognise and celebrate the inspirational people who are making invaluable contributions to our city,” the Lord Mayor said. “It’s the people that make our city the wonderful place it is, and the Melbourne Awards finalists are a testament to our ...

ByCity of Melbourne


Mevion Selected to Equip Compact Proton Therapy Center in Kansas City

Mevion Selected to Equip Compact Proton Therapy Center in Kansas City

Proton therapy is a precise form of radiation therapy that can reduce the amount of unnecessary radiation exposure to healthy tissue, which has the potential to reduce side effects, escalate dose, and lessen the risk of secondary malignancies. ...

ByMevion Medical Systems


TAE Life Sciences to Sponsor Industry Expert Theater “New Era in Biologically-Targeted Radiation Therapy” at 2021 ASTRO Annual Meeting

TAE Life Sciences to Sponsor Industry Expert Theater “New Era in Biologically-Targeted Radiation Therapy” at 2021 ASTRO Annual Meeting

TAE Life Sciences (TLS), a biological-targeted radiation therapy company developing next-generation boron neutron capture therapy (BNCT), today announced the sponsorship of an Industry-Expert Theater session focused on advancements in BNCT at the American Society for Radiation Oncology (ASTRO) Annual Meeting, occurring October 24-27, 2021. The ...

ByTAE Life Sciences (TLS)


Adaptimmune to Present Data Updates at Upcoming CTOS and SITC Meetings

Adaptimmune to Present Data Updates at Upcoming CTOS and SITC Meetings

Clinical update and translational data from SPEARHEAD-1 in patients with synovial sarcoma and MRCLS to be presented at CTOS The Company will host its first virtual medical symposium at CTOS Translational data from Phase 1 SURPASS trial to be presented at SITC Adaptimmune Therapeutics plc (Nasdaq:ADAP), a leader in cell therapy to treat cancer, will present clinical and translational data ...

ByAdaptimmune LLC


New Clinical Trial for Treatment in Prostate Cancer Patients with Specific Genetic Biomarkers

New Clinical Trial for Treatment in Prostate Cancer Patients with Specific Genetic Biomarkers

MiraDx, in collaboration with the UCLA Jonsson Comprehensive Cancer Center, is conducting a clinical trial to validate a novel prostate cancer biomarker panel designed to help assess patients who were at a greater risk of having long-term toxicity in response to their radiation treatment, to help guide treatment decisions. Treatment can involve radiation ...

ByMiraDx

  • Previous
  • Next
Need help finding the right suppliers?Try XPRT Sourcing. Let the XPRTs do the work for you
Back to top
About Medical XPRT

Medical XPRT is a global marketplace with solutions and suppliers for the medical sector, with product catalogs, articles, industry events, publications & more.

Channels

Solutions

  • Medical XPRT Industry Products
  • Medical XPRT Industry Software
  • Medical XPRT Industry Training
  • Medical XPRT Industry Services
  • Medical XPRT Industry Applications

Latest

  • Medical XPRT Industry News
  • Medical XPRT Industry Events

Publications

  • Medical XPRT Industry Articles
  • Medical XPRT Industry Books
  • Medical XPRT Industry Magazines
  • Medical XPRT Industry Downloads
  • Medical XPRT Industry Videos

Companies

  • Medical XPRT Industry Companies

  • FAQs
  • Company sitemap
  • Category sitemap
Medical XPRT is part of XPRT Media All Rights Reserved.
Terms
Privacy
  • Medical XPRT RSS List
Our sites:
Environmental XPRT
Agriculture XPRT
Energy XPRT
XPRT